Parametric Portfolio Associates LLC Has $1.17 Million Stake in Accuray Incorporated (ARAY)
Parametric Portfolio Associates LLC trimmed its stake in Accuray Incorporated (NASDAQ:ARAY) by 33.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,876 shares of the medical equipment provider’s stock after selling 122,538 shares during the period. Parametric Portfolio Associates LLC owned 0.30% of Accuray worth $1,173,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Accuray by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,728,919 shares of the medical equipment provider’s stock worth $31,962,000 after purchasing an additional 281,789 shares in the last quarter. Lapides Asset Management LLC increased its stake in shares of Accuray by 0.3% in the 2nd quarter. Lapides Asset Management LLC now owns 2,221,300 shares of the medical equipment provider’s stock worth $10,551,000 after purchasing an additional 7,500 shares in the last quarter. Royce & Associates LP increased its stake in shares of Accuray by 6.7% in the 2nd quarter. Royce & Associates LP now owns 1,676,077 shares of the medical equipment provider’s stock worth $7,961,000 after purchasing an additional 105,000 shares in the last quarter. Northern Trust Corp increased its stake in shares of Accuray by 4.5% in the 2nd quarter. Northern Trust Corp now owns 1,048,694 shares of the medical equipment provider’s stock worth $4,981,000 after purchasing an additional 45,134 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Accuray by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 858,013 shares of the medical equipment provider’s stock worth $4,076,000 after purchasing an additional 185,519 shares in the last quarter. Hedge funds and other institutional investors own 75.47% of the company’s stock.
Shares of Accuray Incorporated (ARAY) opened at $4.90 on Friday. Accuray Incorporated has a 12 month low of $3.60 and a 12 month high of $6.00. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44.
Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The business had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. During the same quarter in the prior year, the business posted ($0.12) EPS. Accuray’s revenue for the quarter was up 5.2% compared to the same quarter last year. sell-side analysts predict that Accuray Incorporated will post -0.18 EPS for the current fiscal year.
In other Accuray news, COO Kelly Londy sold 99,136 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total value of $420,336.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.90% of the company’s stock.
Several equities research analysts have recently commented on ARAY shares. BidaskClub lowered Accuray from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Zacks Investment Research lowered Accuray from a “hold” rating to a “strong sell” rating in a research note on Monday, July 24th. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Accuray in a research note on Thursday, August 24th. Jefferies Group LLC reduced their price objective on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 23rd. Finally, Cowen and Company reiterated a “buy” rating and issued a $9.00 price target on shares of Accuray in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. Accuray has an average rating of “Hold” and a consensus price target of $6.29.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.